SCHEMBL1817589

SCHEMBL1817589

NC(Cc1ccc(OCc2ccccc2)cc1)C1CO1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 5/20 0.57
MAOB P27338 2/20 0.50
LAP3 P28838 1/20 0.50
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
MAOA P21397 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PPARG P37231 2/20 0.47
PPARA Q07869 2/20 0.47
BCHE P06276 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607825 1.00 LTA4H (0.57) LTA4HMAOBLAP3GAAMAPT
SCHEMBL6562522 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL5732556 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL4912039 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL3670997 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL1817802 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL1683190 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL3870627 0.84 EPHX1 (0.50) LAP3MAOAPTGS1SLC6A2SLC6A3
SCHEMBL19320786 0.83 LTA4H (0.50) LTA4HMAOBMAOARAB9ASMN1; SMN2
SCHEMBL8228429 0.77 SLC6A4 (0.56) CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250108031-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO BACH BIOSCIENCES, LLC 2025-04-03 US disclosed
US-20240398842-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO BACH BIOSCIENCES, LLC 2024-12-05 US disclosed
US-12121505-B2 Fap-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-10-22 US disclosed
US-12053450-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-08-06 US disclosed
CN-113967258-B FAP-activated therapeutic agents and related uses 塔夫茨大学信托人 2024-07-02 CN disclosed
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-07-02 US disclosed
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-03-12 US disclosed
EP-4299134-A2 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO Bach Biosciences, LLC (US) 2024-01-03 EP disclosed
EP-3154594-B1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO BACH BIOSCIENCES LLC (US) 2023-07-19 EP disclosed
US-20220296621-A1 FAP-Activated Therapeutic Agents, and Uses Related Thereto BACH BIOSCIENCES, LLC 2022-09-22 US disclosed
WO-2009149148-A2 LONG-ACTING GLP-1 DERIVATIVES, AND METHODS OF TREATING CARDIAC DYSFUNCTION TRUSTEES OF TUFTS COLLEGE (US) 2009-12-10 WO disclosed
WO-2009006473-A2 PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2009-01-08 WO disclosed
WO-2008128064-A2 TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS TRUSTEES OF TUFTS COLLEGE (US) 2008-10-23 WO disclosed
WO-2008119005-A1 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 WO disclosed
WO-2008118848-A1 N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 WO disclosed
WO-2008116053-A2 FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 WO disclosed
WO-2008116054-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 WO disclosed
WO-2008022015-A2 RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-02-21 WO disclosed
US-20070265255-A1 SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS GEORGETOWN UNIVERSITY 2007-11-15 US disclosed
US-20070110813-A1 Polycation-polyanion complexes, compositions and methods of use thereof AERIS THERAPEUTICS, INC. (US) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12121505-B2 Fap-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 LTA4H 963/4885MAOB 2921/4885LAP3 52/4885
US-20250108031-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO FAP, FIBP, GOT1 LTA4H 963/4885MAOB 2921/4885LAP3 52/4885
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 LTA4H 963/4885MAOB 2921/4885LAP3 52/4885
US-20070265255-A1 SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS ADH5, ADH1C, ADH1A LTA4H 1043/4885MAOB 137/4885LAP3 1842/4885
US-20220296621-A1 FAP-Activated Therapeutic Agents, and Uses Related Thereto FAP, FIBP, GOT1 LTA4H 966/4885MAOB 3325/4885LAP3 57/4885
US-12053450-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 LTA4H 963/4885MAOB 2921/4885LAP3 52/4885
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 LTA4H 966/4885MAOB 3325/4885LAP3 57/4885
US-20240398842-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO FAP, FIBP, GOT1 LTA4H 954/4885MAOB 3271/4885LAP3 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.